



Dear 340B Covered Entities,

I am writing to inform you that Liquidia has implemented a policy for distributing products purchased at the 340B price. Consequently, effective August 1<sup>st</sup>, 2025, Liquidia will ship Yutrepia™ (Treprostinil) inhalation powder (Yutrepia™) purchased at the 340B price exclusively to locations within Liquidia's limited distribution network (Accredo or Caremark/CVS).

Covered Entities that wish to place replenishment orders of Yutrepia™ may designate a single Accredo or Caremark/CVS Specialty contract pharmacy location. The covered entity must agree to provide claims data for the designated single contract pharmacy within 45 days of the date of dispense.

Liquidia would like to remind Covered Entities that access to 340B pricing is premised on (i) Covered Entities' remaining responsible for and maintaining title to the 340B Drug from the date of acquisition until final dispensing to Covered Entities' eligible patients, and (ii) Covered Entities remaining in compliance with all applicable laws including, but not limited to, the Drug Supply Chain Security Act and state distribution and wholesaler licensing restrictions. Accordingly, Covered Entities may ship Yutrepia™ purchased at the 340B price only through Liquidia's limited distribution network (Accredo or Caremark/CVS) and only to the location of final dispense of Yutrepia™ to patient.

Non-transparent arrangements, including but not limited to alternative distribution models which result in the product being diverted, resold or dispensed outside of a Covered Entity's designated contract pharmacy, or other arrangements such as "banking" orders, virtual returns or credits; fall outside of this policy and the 340B program and may result in chargeback reversal or other action at the discretion of Liquidia. Liquidia also reserves the right to suspend sales of Yutrepia™ at the 340B price to Covered Entities that are not in compliance with applicable federal, state or local law, including but not limited to the federal statutory diversion and duplicate discount prohibitions (42 U.S.C. § 256b(a)(5)(A)-(B)).

Liquidia is utilizing the 340B ESP™ platform to support this designation and claims submission. 340B covered entities can register an account and make their designations by visiting [www.340besp.com/designations](http://www.340besp.com/designations). Users that have registered an account with 340B ESP™ can designate a contract pharmacy by navigating to the Entity Profile tab. If you have questions regarding this policy, please contact [support@340Besp.com](mailto:support@340Besp.com).

This policy is subject to the following exceptions:



Covered entities located in Hawaii, Louisiana, Kansas, Maryland, Missouri, Minnesota, and Mississippi can continue to place bill to/ship to replenishment orders at unlimited contract pharmacies as long as they are part of Liquidia's limited distribution network (Accredo or Caremark/CVS) and are listed on the HRSA OPA database as a covered entity's contract pharmacy. Covered entities in these states must agree to provide claims data for each designated contract pharmacy within 45 days of the date of dispense.

Covered entities located in Colorado, Oregon (effective 9/26/2025), Maine (effective 9/24/2025), Nebraska, North Dakota, Rhode Island (effective 10/01/2025), South Dakota, Tennessee, Vermont, Utah and West Virginia can continue to place bill to/ship to replenishment orders at unlimited contract pharmacies as long as they are part of Liquidia's limited distribution network (Accredo or Caremark/CVS) and are listed on the HRSA OPA database as a covered entity's contract pharmacy. Covered entities in these states are not required to provide claims data.

Covered entities located in Arkansas can continue to place bill to/ship to replenishment orders at unlimited contract pharmacies located within the State of Arkansas and outside of Liquidia's limited distribution network as long as they are listed on the HRSA OPA database as covered entity's contract pharmacy. Covered entities located in Arkansas can also continue to place bill to/ship to replenishment orders at unlimited contract pharmacies within Liquidia's limited distribution network. In either case, covered entities located in Arkansas are not required to provide claims data.

Liquidia continues to monitor state level 340B contract pharmacy requirements and reserves the right to make additional modifications to the above policy, including but not limited to re-instituting the terms of prior policies.

Best regards,

*Frank Bartolini*

Frank Bartolini

Sr. Vice President Market Access



## **Frequently Asked Questions**

### **Q: Which products are covered under Liquidia's contract pharmacy policy?**

A. Currently, Yutrepia™ will be the only product covered under Liquidia's contract pharmacy policy. Liquidia reserves the right to add additional products to this policy in the future.

### **Q: Why does Liquidia have a limited distribution network for Yutrepia™?**

A. Yutrepia™ is a highly specialized medication for patients suffering from a rare and progressive disease. As such patients taking Yutrepia™ require an unusual degree of instruction, follow-up and ongoing support. Therefore, because patient safety is our number one priority, Liquidia makes these drugs available only through certain specialized pharmacies (Accredo and Caremark/CVS) that were selected after a strict selection process, and which have special experience, trained personnel and logistical capabilities to properly support patients suffering from this devastating disease.

### **Q: Which covered entities are subject to Liquidia's new contract pharmacy policy?**

A. All eligible 340B covered entities, including federal grantees eligible for 340B participation under 42 U.S.C. § 256b(a)(4)(A)-(K), are subject to this new contract pharmacy policy.

### **Q. My 340B covered entity has contract pharmacy arrangements with multiple locations of the same pharmacy company. Can my entity designate all locations of the same pharmacy company?**

A. No, Covered Entities can designate a single Accredo or Caremark/CVS Specialty contract pharmacy location can be designated via the Designations form on [www.340besp.com/designations](http://www.340besp.com/designations) unless there is a State exemption as described below.

### **Q. How often can a covered entity change its contract pharmacy location designation?**



A. A covered entity can change its contract pharmacy location designation once every twelve (12) months. A covered entity may change its contract pharmacy location designation within a 12-month period only if the designated contract pharmacy location is terminated as a contract pharmacy of the covered entity from the 340B OPAIS database.

**Q. How would a covered entity change its contract pharmacy location designation?**

A. Changes to a contract pharmacy location designation can be made at [www.340besp.com/designations](http://www.340besp.com/designations).

**Q. How long does it take after a contract pharmacy designation is made for it to be effective?**

A. It may take up to ten (10) business days to gain eligibility after the designation has been completed.

**Q. Is Liquidia requiring covered entities to have a HIN registered for the contract pharmacy that they designate?**

A. Yes, a contract pharmacy must have a HIN assigned to it in order for a covered entity to designate it as its single contract pharmacy. This information is important for Liquidia to manage its process with its wholesalers.

**Q. If the contract pharmacy my covered entity wants to designate doesn't have a HIN, how does my entity get one?**

A: Liquidia will not register a HIN on your behalf, however if you need guidance or more information on how to get a HIN assigned to your contract pharmacy, please reach out to [support@340besp.com](mailto:support@340besp.com). If you try to designate a contract pharmacy without a HIN in 340B ESP™, the system will notify you of this requirement and provide instructions for how to obtain a HIN.

**Q: My covered entity would like to submit 340B claims for its contract pharmacy and purchase Yutrepia™ at the 340B price. What does our entity need to do to begin submitting 340B claims?**



A: 340B covered entities that wish to submit 340B claims under Liquidia's policy can do so by registering an account at [www.340Besp.com](http://www.340Besp.com). Users that have registered an account with 340B ESP™ can begin submitting 340B claims for Liquidia by navigating to the Claims Data Submission tab.

**Q: We are a 340B covered entity in [Arkansas / Colorado/ Hawaii / Kansas / Louisiana / Maine / Maryland / Minnesota / Missouri / Mississippi / Nebraska / North Dakota / Oregon / Rhode Island / South Dakota / Tennessee / Utah / Vermont / West Virginia]. Do we need to register an account with 340B ESP™ and make a contract pharmacy designation and submit claims data as required under Liquidia's policy?**

A: Covered entities located in Hawaii, Kansas, Louisiana, Maryland, Minnesota, Missouri, and Mississippi will not have to make contract pharmacy designations within Liquidia's limited distribution network and will have to provide claims data for each designated contract pharmacy to maintain access to Yutrepia™ at the 340B price. Covered entities in these states can continue to place bill to/ship to replenishment orders at unlimited contract pharmacies within Liquidia's limited distribution network.

Covered entities in Colorado, Oregon, Maine, Nebraska, North Dakota, Rhode Island, South Dakota, Tennessee, Utah, Vermont or West Virginia, will not have to make contract pharmacy designations within Liquidia's limited distribution network and will not have to provide claims data for each designated contract pharmacy to maintain access to Yutrepia™ at the 340B price. Covered entities in these states can continue to place bill to/ship to replenishment orders at unlimited contract pharmacies within Liquidia's limited distribution network.

Covered entities in Arkansas will not have to make contract pharmacy designations within Liquidia's limited distribution network or for contract pharmacies located within the State of Arkansas. In either case, covered entities located in Arkansas are not required to provide claims data.